Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Management to Host Conference Call

BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.

The live conference call may be accessed here and on the Company’s website under Events and Presentations.

The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our website.

For more information:

Investor inquiries:   
Fred Ahlholm
CFO, Minerva Neurosciences
info@minervaneurosciences.com

Media Inquiries:
Helen Shik
Principal, Shik Communications LLC
helen@shikcommunications.com

Staff

Recent Posts

PDS Health and DEXIS Successfully Bring AI-Powered and 3D Imaging to More Than 1,000 Dental Practices Nationwide

Strategic collaboration brings advanced AI and CBCT imaging to more than 1,000 dental practices, enhancing…

1 hour ago

Exactech Reaches Consensual Agreement with Unsecured Creditors Committee, Completes Court Filing of Amended Plan

Plan Confirmation and Sale Approval Court Date Expected in Early September GAINESVILLE, Fla., July 24,…

1 hour ago

Tali AI Joins QHR’s Marketplace to Bring AI Scribing to Accuro®EMR Users

TORONTO, July 24, 2025 /CNW/ - Tali AI, the leading Canadian healthtech company focused on reducing…

1 hour ago

Diabetes Diagnostics Enters New Era: Kalorama Highlights Digital Shift and Global Surge in HbA1c Testing

ARLINGTON, Va., July 24, 2025 /PRNewswire/ -- The global fight against diabetes is accelerating—and diagnostic innovation…

1 hour ago

123Invent Inventor Develops Electronic Display Board for Maternity Wards (MBQ-725)

PITTSBURGH, July 24, 2025 /PRNewswire/ -- "I thought there should be a way to keep…

1 hour ago